midomafetamine (MDMA) / Lykos Therapeutics 
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
midomafetamine (MDMA) / Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPPUSX, NCT04714359: A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

Completed
3
85
Canada, US, RoW
Midomafetamine, 3,4-methylenedioxymethamphetamine, MDMA
Lykos Therapeutics
PTSD
11/23
11/23
NCT04030169 / 2018-001718-13: Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

Completed
2
21
Europe, RoW
MDMA, 3,4-methylenedioxymethamphetamine
MAPS Europe B.V., Multidisciplinary Association for Psychedelic Studies
PTSD
12/23
12/23
NCT05067244: A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)

Active, not recruiting
2
10
Canada
MDMA
Remedy, Multidisciplinary Association for Psychedelic Studies
Post Traumatic Stress Disorder
06/24
06/24
MED1, NCT04454684: A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders

Not yet recruiting
2
36
NA
Midomafetamine, 3,4-methylenedioxymethamphetamine, MDMA, Non-directive therapy, Manualized MDMA-assisted therapy, Therapy
Lykos Therapeutics
Anorexia Nervosa Restricting Type, Binge-Eating Disorder
08/28
08/28
NCT03606538: MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

Not yet recruiting
1
16
US
Midomafetamine, MDMA, 3,4-methylenedioxymethamphetamine
Lykos Therapeutics
Pharmacokinetics, Hepatic Impairment
12/28
12/28
EAMP1, NCT04438512: A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD

No Longer Available
N/A
US
Midomafetamine, 3,4-methylenedioxymethamphetamine, MDMA, Psychotherapy
Lykos Therapeutics
Post Traumatic Stress Disorder
 
 

Download Options